CD47 and Sezary syndrome: Cutaneous T-cell lymphoma (CTCL) is not an exception; moreover, significant overexpression of CD47 in Sézary syndrome [14] and mycosis fungoides [15] makes CTLC an ideal candidate for anti-CD47 therapy.